News|Articles|August 17, 2023

Bios Health Group Enters Life Sciences Market

Bios Health Group has entered the life sciences market. This new company entity is a strategic partner providing solutions for life science companies and investors. It offers strategies to attract funding, optimize clinical development, and create effective commercial strategies. Bios Health Group also serves as a venture partner providing investor preparation for Bbotech companies seeking investment funding and access to venture funds through its investor networks.

Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP^® said in a press release, "We are thrilled to bring this comprehensive suite of end-to-end solutions to biotech and life science companies. Our strategic approach involves engagement with venture capitalists and investors, effectively addressing the funding gap that often impedes early-stage biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide established companies with proven commercial strategies to launch new products and expand their market presence."

Bios Health Group offers four strategic solutions:

BioInvest offers life science companies guidance on investment preparation including business plans, investor attractive investment pitches, and access to investor networks.
Innovate Bio focuses on clinical development optimization, prioritizing R&D indications and pipelines to maximize value, leveraging innovations, strategic and patient-centric approaches to optimize and accelerate clinical development.
CRO Select helps Biotech companies select the right fit CRO.
LaunchMax offers commercial strategy development and execution. In addition, the BIOS Innovation Circle brings together strategic experts to provide tailored solutions.

Reference

Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies. (2023, August 15). Cision PR Newswire.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 30th, 2026

The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials

AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.

© FlowStudio - © FlowStudio - stock.adobe.com

September 29th, 2026

Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.

September 29th, 2026

The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.

September 29th, 2026

ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

September 28th, 2026

Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD

In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.

September 28th, 2026

The Design Flaws Trial Simulations Surface That Traditional Planning Misses

In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.